Biotechnology/Chemical/Pharmaceutical Customer Partnership January 14, 2003
Tuesday, January 14, 2003
United States Patent and Trademark Office
Arlington, Virginia 22202
Crystal Square 4, 7
th
Floor, Room 1
The most recent quarterly meeting for the Biotechnology and Chemical Pharmaceutical Customer Partnership was held on October 8, 2002, at the U.S. Patent and Trademark Office. The Biotechnology and Chemical Pharmaceutical Customer Partnership is designed and developed to be a forum to share ideas, experiences, and insights between individual users and the USPTO. The USPTO does not intend to use these customer partnership groups to arrive at any consensus. Invitations to participate will indicate that individual opinions are sought, rather than a group consensus and that the meetings are intended to be informal in nature and have varying participants. These customer partnership groups are formed with full recognition of the USPTO's responsibility under the Federal Advisory Committee Act (FACA), and that these customer partnership groups are not established as FACA compliant committees.
We value our customers in obtaining feedback from individual participants is important in our efforts to continuously improve the quality of our products and services. Your willing participation is helpful in providing us with insights and experiences in this informal process to assist us.
The next meeting of the US Patent and Trademark Office Biotechnology and Chemical Pharmaceutical Customer Partnership is scheduled for Tuesday January 14, 2003 from 9:00 am to 4:30pm in Crystal Square 4 suite 700, located on 1745 Jefferson Davis Highway in Arlington, Virginia.
Please contact Cecilia Tsang at 703-308-0254 or by fax at 703-746-7144 or email Cecilia.Tsang@uspto.gov or contact Sharlamar Taliaferro at 703-306-4094 or by fax 703-305-8002 or email Sharlamar.Taliaferro@uspto.gov to decline or confirm your attendance.
Biotechnology/Chemical/Pharmaceutical Customer Partnership
Tuesday, January 14th, 2003
United States Patent and Trademark Office
Arlington, Virginia 22202
Crystal Square 4, 7
th
Floor, Room 1
Morning Session | ||
Time | Subject | Speaker |
---|---|---|
9:00-9:15 AM | Greetings and Overview | Jasemine Chambers
John Doll Bruce Kisliuk Directors, TC 1600 |
9:15-9:30 AM | "Official Notice" taken in Office actions | John Doll |
9:30-10:15 AM | Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities | Deborah Reynolds
Supervisory Patent Examiner Technology Center 1600 |
10:15-10:30 AM | Break | |
10:30-11:15 AM | Sequence Searches and Analysis | Christopher Low
Supervisory Patent Examiner Technology Center 1600 |
11:15 - 11:45 AM | 102 (e) and 102 (g) | Rob Clarke, OPLA |
11:45 AM -1:15 PM | Lunch Break |
Afternoon Session | ||
Time | Subject | Speaker |
---|---|---|
1:15 - 2:00 PM | Rule 132 Declarations and Unexpected Results | Paula Hutzell
Practice Specialist Technology Center 1600 |
2:00 - 2:45 PM | Non-Functional Descriptive Material: 3-D Structures and Computer Algorithms | Michael Woodward
Supervisory Patent Examiner Technology Center 1600 |
2:45 - 3:00 PM | Break | |
3:00 - 4:00 PM | Interpartes Reexamination Changes | Ken Schor, OPLA |
4:00 - 4:15 PM | Wrap Up | Jasemine
Chambers
John Doll Bruce Kisliuk Directors, TC 1600 |